0001752724-24-098712.txt : 20240514 0001752724-24-098712.hdr.sgml : 20240514 20240514144457 ACCESSION NUMBER: 0001752724-24-098712 CONFORMED SUBMISSION TYPE: N-CEN PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240229 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 EFFECTIVENESS DATE: 20240514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JPMorgan Institutional Trust CENTRAL INDEX KEY: 0001303608 ORGANIZATION NAME: IRS NUMBER: 201491791 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: N-CEN SEC ACT: 1940 Act SEC FILE NUMBER: 811-21638 FILM NUMBER: 24943554 BUSINESS ADDRESS: STREET 1: 277 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10172 BUSINESS PHONE: 800-480-4111 MAIL ADDRESS: STREET 1: 277 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10172 0001303608 S000007337 JPMorgan Core Bond Trust C000020141 JPMorgan Core Bond Trust N-CEN 1 primary_doc.xml X0404 N-CEN LIVE 0001303608 XXXXXXXX 811-21638 true false false N-1A S000007337 true JPMorgan Institutional Trust 811-21638 0001303608 5493005FRK56SHN6MJ34 277 Park Avenue New York 10172 US-NY US 800-480-4111 JPMorgan Chase Bank, N.A. 383 Madison Avenue New York 10179 212-270-6000 Records relating to its functions as sub-administrator and fund accounting agent J.P. Morgan Institutional Investments, Inc. 383 Madison Avenue New York 10179 201-595-1958 Records relating to its functions as placement agent DST Asset Manager Solutions, Inc. 2000 Old Colony Drive Quincy 02169 617-483-5000 Records relating to its functions as transfer agent JPMorgan Chase Bank, N.A. 4 Chase Metrotech Center Brooklyn 11245 718-242-0609 Records relating to its functions as custodian J.P. Morgan Investment Management Inc. 383 Madison Avenue New York 10179 800-343-1113 Records relating to its functions as investment adviser and administrator N N N-1A 1 N Lawrence R. Maffia N/A N Robert J. Grassi 006093150 N John F. Finn N/A N Marian U. Pardo N/A N Frankie D. Hughes N/A N Raymond Kanner N/A N Stephen P. Fisher N/A N Nina O. Shenker N/A Y Emily A. Youssouf N/A N Gary L. French N/A N Marilyn McCoy N/A N Kathleen M. Gallagher N/A N Mary E. Martinez N/A N Robert F. Deutsch N/A Y Thomas P. Lemke N/A N Dr. Robert A. Oden, Jr. N/A N Stephen M. Ungerman 002315698 277 Park Avenue New York 10172 XXXXXX N N N N N N JPMorgan Distribution Services, Inc. 8-52700 000104234 N/A Y N PricewaterhouseCoopers LLP 238 5493002GVO7EO8RNNS37 N N N N N N N JPMorgan Core Bond Trust S000007337 549300Q7485FUJKEMM46 N 0 0 0 N/A N N Y N Citibank N.A. E57ODZWZ7FF32TWEFA76 N N Revenue sharing split Cash collateral reinvestment fee 0.00000000 0.00000000 Rule 32a-4 (17 CFR 270.32a-4) Rule 18f-4(c)(4) (17CFR 270.18f-4(c)(4)) Rule 10f-3 (17 CFR 270.10f-3) Rule 12d1-1 (17 CFR 270.12d1-1) Rule 18f-4 (17 CFR 270.18f-4) Rule 12d1-4 (17 CFR 270.12d1-4) Y Y N N J.P. Morgan Investment Management Inc. 801-21011 000107038 549300W78QHV4XMM6K69 N DST Asset Manager Solutions, Inc. 84-00896 N/A N N N Bloomberg L.P. 549300B56MD0ZC402L06 N PricingDirect Inc. 549300WIC0TOJ7N7GD54 Y LSEG 2138007FV67QQ13CGJ43 N ICE Data Pricing & Reference Data, LLC 5493000NQ9LYLDBCTL34 N N BofA Securities, Inc. 549300HN4UKV1E2R3U73 N Y Futures commission merchants and commodity clearing organizations - rule 17f-6 (17 CFR 270.17f-6) JPMorgan Chase Bank, N.A. 7H6GLXDRUGQFU57RNE97 Y N Self - rule 17f-2 (17 CFR 270.17f-2) N N J.P. Morgan Investment Management Inc. 549300W78QHV4XMM6K69 Y N JPMorgan Chase Bank, N.A. 7H6GLXDRUGQFU57RNE97 Y Y N Goldman Sachs & Co. LLC 8-00129 000000361 FOR8UP27PHTHYVLBNG30 2038.00000000 Citigroup Global Markets Inc. 8-08177 000007059 MBNUM2BPBDO7JBLYG310 13838.85000000 Deutsche Bank Securities Inc. 8-17822 000002525 9J6MBOOO7BECTDTUZW19 2521.80000000 Barclays Capital, Inc. 8-41342 000019714 AC28XWWI3WIBK2824319 9055.04999999 27453.70000000 Wells Fargo Securities, LLC 8-65876 000126292 VYVVCKR63DVZZN70PB21 73327859.45999999 Goldman Sachs & Co. LLC 8-00129 000000361 FOR8UP27PHTHYVLBNG30 199912807.62000000 BMO Nesbitt Burns Securities Ltd. 8-50538 000044057 M3LKFDNSJGJ7TMLH6Z15 CA 66369680.68000000 BNP Paribas Securities Corp. 8-32682 000015794 RCNB6OTYUAMMP879YW96 111578268.97000000 BofA Securities, Inc. 8-69787 000283942 549300HN4UKV1E2R3U73 174963611.59999999 Barclays Capital, Inc. 8-41342 000019714 AC28XWWI3WIBK2824319 137058553.22000000 RBC Capital Markets, LLC 8-45411 000031194 549300LCO2FLSSVFFR64 53508512.67000000 Citigroup Global Markets Inc. 8-08177 000007059 MBNUM2BPBDO7JBLYG310 90670206.04000000 Morgan Stanley & Co. LLC 8-15869 000008209 9R7GPTSO7KV3UQJZQ078 111195389.61000000 Citadel Securities LLC 8-53574 000116797 12UUJYTN7D3SW8KCSG25 30633134.77000000 1306604678.97000000 N 2128697938.12000000 Uncommitted 100000000.00000000 N Committed 1500000000.00000000 N N N N false false true false false false INTERNAL CONTROL RPT 2 JPM_INSTT_Trust.htm HTML

Report of Independent Registered Public Accounting Firm

To the Board of Trustees of JPMorgan Institutional Trust and Shareholders of JPMorgan Core Bond Trust

In planning and performing our audit of the financial statements of JPMorgan Core Bond Trust (the “Fund”) as of and for the year ended February 29, 2024, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), we considered the Fund’s internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Fund’s internal control over financial reporting. Accordingly, we do not express an opinion on the effectiveness of the Fund’s internal control over financial reporting.

The management of the Fund is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A fund’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A fund’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the fund; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the fund are being made only in accordance with authorizations of management and trustees of the fund; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a fund’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the fund’s annual or interim financial statements will not be prevented or detected on a timely basis.

Our consideration of the Fund’s internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control over financial reporting that might be material weaknesses under standards established by the PCAOB. However, we noted no deficiencies in the Fund’s internal control over financial reporting and its operation, including controls over safeguarding securities, that we consider to be material weaknesses as defined above as of February 29, 2024.

This report is intended solely for the information and use of the Board of Trustees of JPMorgan Institutional Trust and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.

/s/ PricewaterhouseCoopers LLP

New York, New York

April 24, 2024